SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after discontinuing its recently launched compounded semaglutide pill following regulatory scrutiny and legal threats, fueling a polarized community debate between those anticipating further stock decline due to perceived management missteps and others expecting a rebound as regulatory overhang is removed and a Super Bowl ad airs.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is experiencing intense discussion ahead of record Super Bowl betting volume, with community sentiment sharply divided between the escalating competitive challenge from prediction markets and the highly anticipated upcoming earnings report, especially as the company expands its own prediction offerings.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

DOJ scrutiny of Netflix's Warner Bros. Discovery bid is shifting market sentiment, with the community actively discussing how this could favor Paramount Skydance's counter-offer, which is further buoyed by the highly successful debut of UFC content on Paramount+.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending following a high-impact Super Bowl commercial for its Briumvi drug and strong preliminary revenue guidance, fueling community discussion about Briumvi's growing market share and best-in-class profile. Many investors are highlighting its efficacy and safety against competitor drug concerns, yet express frustration over the stock's valuation disconnect and actively discuss a potential buyout to realize its full value.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending ahead of its Q4 earnings report on Monday, with the community highly anticipating a strong beat and solid 2026 guidance for its AI-powered credit platform. Investors are keenly watching for a potential short squeeze, believing the stock remains significantly undervalued despite recent market volatility and fresh funding agreements.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after announcing a $250 million financing amendment extending its capital runway through 2028, triggering widespread community speculation for a potential short squeeze, though some caution against its history of volatility and concerns over dilution.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community sentiment soars after Hims & Hers pulled its compounded weight-loss pill following regulatory scrutiny and NVO's legal threats, reinforcing the competitive advantage of approved GLP-1 therapies. Many anticipate a significant boost to NVO's market share for its Wegovy pill, with additional buzz surrounding its Super Bowl commercial amplifying discussions on potential sales impact.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a broader software sector sell-off driven by fears that AI will disrupt established business models, despite the company securing a significant $5.6 billion U.S. Army contract and actively integrating AI through initiatives like Agentforce. The community is sharply divided between those viewing the current dip as a generational buying opportunity and those concerned about a lasting valuation reset for enterprise SaaS.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending as its new partnership with Palantir Technologies and prime contract for the U.S. Missile Defense Agency's SHIELD Program underscore its pivotal role in AI data engineering. Investors are keenly watching for potential major revenue expansion in defense, government, and sovereign AI, viewing the company as a critical, undervalued player in the booming AI ecosystem.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings Inc. is soaring after reporting an impressive earnings beat and strong forward guidance, fueling investor excitement around its critical role in providing optical components like circuit switches and co-packaged optics for rapidly expanding AI data centers. The market is buzzing with bullish sentiment and numerous analyst upgrades, recognizing LITE as a key beneficiary of the 'AI plumbing' supercycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus bacteremia, with no relapses reported.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.</li><li>Retail traders flooded Stocktwits with bullish posts after the record rally, with some predicting further gains while others expected a share offering.</li></ul>Shares of Armata Pharmaceuticals surged to a record high on Wednesday after the company reported encouraging Phase 2a results for its experimental bacteriophage therapy, AP-SA02, in patients with complicated Staphylococcus aureus bacteremia (SAB), a serious and often life-threatening bloodstream infection.The stock logged its best session on record on Wednesday, surging 103% to close at $7.05, and fell 16% in after-hours trading as investors took profits following the steep rally.Promising Results In Early-Stage TrialThe findings show for the first time, in a randomized trial, that intravenous phage therapy can be efficacious for S. aureus bacteremia.&nbsp;The diSArm study showed that patients treated with AP-SA02 in addition to the best available antibiotic therapy had an 88% clinical response rate at day 12, compared with 58% for placebo. No patients treated with AP-SA02 relapsed or were non-responsive, versus approximately 25% of patients who received&nbsp;a placebo.A total of 42 patients were enrolled in the trial, and about 38% of the cases had infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Armata said that the treatment was well-tolerated with no serious adverse events associated with the drug.The company is looking to move AP-SA02 into a Phase 3 trial in 2026, based on these results, subject to regulatory input from the U.S. Food and Drug Administration.Analyst ViewH.C. Wainwright reaffirmed its ‘Buy’ rating and $9 price target on Armata, representing a 28% upside from the company’s last close. The brokerage said the results, along with supporting in vitro data, provide “strong evidence for the efficacy of its core therapeutic strategy.” The firm said the data support moving the bacteriophage therapy into a pivotal late-stage study next year.Multi-Phage Cocktail Shows Broad Efficacy&nbsp;Armata said AP-SA02, a fixed cocktail of multiple bacteriophages, showed consistent efficacy against both MRSA and methicillin-sensitive S. aureus (MSSA) and was linked to faster infection clearance and shorter hospital stays. The company received $26.2 million in funding from the U.S. Department of Defense through the Medical Technology Enterprise Consortium to support the diSArm study.Stocktwits Traders See Potential Stock Offering&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 26,200% surge in 24-hour message volume.One user said they expected the company to announce a share offering following the surge in its stock price.<stembedurl>https://stocktwits.com/FredDurst/message/633328173</stembedurl>Another user, however, struck an optimistic tone, predicting that the stock could double in value the next day.<stembedurl>https://stocktwits.com/Lifeinlight/message/633324622</stembedurl><a href="https://stocktwits.com/symbol/ARMP">Armata’s stock</a> has&nbsp;rocketed 281% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Armata Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In

H.C. Wainwright reiterated a ‘Buy’ rating and $9 target, saying the results support advancing AP-SA02 into Phase 3 next year.

Equity

Are Medical Stocks Lagging  Armata Pharmaceuticals (ARMP) This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

ARMP
Armata Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARMP News

ARMPArmata Pharmaceuticals Inc